Involvement of RUVBL1 in WNT/β-Catenin Signaling in Oral Squamous Cell Carcinoma

Yongfa Zeng,1 Ying Kong,2 Lan Liao,1 and Hongshui Zhu1

1The Affiliated Stomatological Hospital of Nanchang University, The Key Laboratory of Oral Biomedicine, Jiangxi Province, Jiangxi Province Clinical Research Center for Oral Diseases, Nanchang City, 330006, Jiangxi Province, China
2The First Affiliated Hospital of Nanchang University, Nanchang City, 330006, Jiangxi Province, China

Correspondence should be addressed to Hongshui Zhu; ndfskqyy136@ncu.edu.cn

Received 28 June 2021; Revised 10 January 2022; Accepted 14 March 2022; Published 22 April 2022

Copyright © 2022 Yongfa Zeng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Oral squamous cell carcinoma (OSCC) is the most common malignant tumor of head and neck squamous cell carcinoma (HNSCC), but the causes and molecular mechanisms remain unclear. The wingless-integrated/β-catenin (WNT/β-catenin) signaling pathway plays a vital role in cancer cell proliferation, differentiation, and metastasis, including OSCC. To screen potential β-catenin-associated genes involved in OSCC, the intersection of these genes in the STRING and IMEx databases was assessed using differential expression genes (DEG) from public microarrays, and 22 were further selected to construct a β-catenin-protein interaction network. The top 14 hub genes (node degree > 10) within the network were selected. Pearson’s correlation analysis showed that β-catenin expression correlated positively with the expression of 11 genes, including AR, BIRC5, CDK6, DKK1, GSK3B, MET, MITF, PARD3, RUVBL1, SLC9A3R1, and SMAD7. A heat map of overall hub gene survival was created, and elevated expression of DKK1 and RUVBL1 was associated with poor survival using the Mantel-Cox test. To identify the function of RUVBL1, colony formation assay, transwell assay, and western blotting revealed that knockdown of RUVBL1 by siRNA decreased H157 and Cal-27 cell proliferation and metastasis by inhibiting β-catenin signaling. These findings suggest that RUVBL1 may serve as a diagnostic and prognostic biomarker for OSCC, as well as a therapeutic target, and may help to uncover additional molecular mechanisms of β-catenin-driven OSCC tumorigenesis.

1. Introduction

Oral squamous cell carcinoma (OSCC) is the most frequent malignant tumor of head and neck squamous cell carcinoma (HNSCC) [1]. Incidence and mortality have increased in recent years worldwide [2]. At the same time, many of the causes and mechanisms underlying OSCC progression remain unclear. The wingless-integrated/β-catenin (WNT/β-catenin) signaling pathway is composed of ligands, receptors, and coreceptors that are associated with signal transduction and induce a variety of intracellular responses. aberrant activation of WNT/β-catenin signaling is found in many types of tumors and plays an intrinsic role in cancer cell proliferation, differentiation, metastasis, and other functions [3]. WNT/β-catenin signaling is considered the most important signaling pathway in OSCC [3]. Several hub genes involved in WNT/β-catenin signaling pathway have been identified as therapeutic targets and diagnostic biomarkers of OSCC [3], including DAB2 [4], Msi2 [5], E-cadherin, and β-catenin [6]. Alteration of membrane and nuclear expression of β-catenin are closely correlated with differentiation, invasion, and poor prognosis [7, 8]. In addition, the shift from membrane to cytoplasmic expression of E-cadherin (73.3%) and β-catenin (78.3%) in OSCC correlates with histologic grade [9]. Other studies have shown that nuclear β-catenin staining is a potential prognostic marker for ovarian cancer in univariate analysis, while cytoplasmic and membranous β-catenin staining is not [10]. The epithelial-mesenchymal transition (EMT) is a vital process in cancer development and progression. Cancer cells experiencing EMT can migrate from the original tissue and invade stromal tissues and more distant regions [11]. OSCC tissue has an active EMT phenotype as compared with
normal oral mucosa. This phenotype includes decreased E-cadherin and increased N-cadherin and β-catenin expression in the nucleus [9, 12]. Thus, it is important to conduct a thorough inquiry into the relationship between β-catenin and the related gene expression and clinicopathological features of OSCC patients in China.

In the present study, an integrated method to screen β-catenin-associated genes (BCAGs) was developed. A flowchart of the analysis pipeline is shown in Figure S1. First, a β-catenin-protein interaction network was constructed, and several hub genes were screened out based on differential expression of genes (DEGs), nodes were connected within the network, and the outcome of overall survival (OS) was measured. RUVBL1, also known as Pontin protein, was associated with low survival rates. Therefore, it was postulated that RUVBL1 may serve as a potential diagnostic and prognostic biomarker, as well as a therapeutic target against OSCC, and may help to define the molecular mechanisms of β-catenin-induced tumorigenesis in OSCC.

2. Materials and Methods
2.1. Data Collection and OSCC Patients. OSCC microarray datasets of GSE30784 (OSCC n = 164 and adjacent
nontumor tissue \( n = 45 \), GSE37991 (OSCC \( n = 40 \) and adjacent nontumor epithelial tissue \( n = 40 \)), and GSE31056 (OSCC \( n = 21 \) and adjacent nontumor tissue \( n = 24 \)) were obtained and downloaded from the NCBI Gene Expression Omnibus (GEO) (https://www.ncbi.nlm.nih.gov/geo/) using the R package, "GEOquery." R packages "limma" and "ggstatsplot" were used to annotate all probes and produce a differential expression matrix. After data preprocessing, \( p < 0.05 \) and \( |\log_2 \text{FC}| \geq 1 \) (FC, fold change) were defined as the threshold to screen differential expression genes (DEGs). Principal component analysis (PCA) was also performed using "prcomp" in R studio.

2.2. Selection of Hub Genes by β-Catenin-Protein Interaction Network and Functional Annotation. To identify BCAGs in OSCC, β-catenin-associated protein (BCAP) interaction network was constructed through STRING and IMEx database by Networkanalyst (https://www.networkanalyst.ca/).
Venn plot (http://bioinfogp.cnb.csic.es/tools/venny/index.html) was visualized by identifying genes that intersected among DEGs and genes from STRING and IMEX. The selected DEGs were further used to construct a β-catenin-associated protein interaction network using Networkanalyst and visualized by Cytoscape [13]. After the rank of node degree, node genes (node degree > 10) were considered as hub genes associated with β-catenin. Hub gene expression was also shown by box plot using GSE datasets. Correlation analysis between β-catenin and hub gene expression was analyzed by Pearson’s correlation analysis using HNSC data from the Gene Expression Profiling Interactive Analysis (GEPIA) (http://gepia.cancer-pku.cn/) database. A p value < 0.05 was considered significant.

2.4. Immunohistochemistry (IHC). Tissue microarray of OSCC (Cat # TC0224) including 50 OSCC samples and ten normal oral tissue samples was purchased from the Auragen Bioscience Company (Changsha, China). RUVBL1 protein levels were detected by tissue microarray using anti-RUVBL1 antibody (Cat # sc-393905, Santa Cruz, Shanghai, China) followed by an SV-DAB two-step kit (Cat # SV0004, Boster Biological Technology Company, China). Several serial 4 μm thick sections were cut and mounted on silanized slides. After several steps of deparaffinizing, rehydrating, and blocking with endogenous peroxidase, the sections were rinsed with 0.01 M PBS and incubated in blocking buffer (0.01 M PBS, 0.3% Triton X-100, and 5% normal goat serum) for 30 min. The slides were then exposed to 1:100 primary anti-RUVBL1 antibody overnight. After further incubation with the secondary HRP-antibody (Cat # BA1055, Boster, China) for 30 min at 37°C, the slides were washed five times with PBS. The chromogenic reaction was performed using freshly prepared diaminobenzidine (DAB) for 10 min and Harris hematoxylin. Hamamatsu NanoZoomer RS Digital Pathology System
The cells that migrated to the scratched area were examined under a microscope after 48 h.

The Cal-27 cell line was pur chased from the Cell Resource Center, Chinese Academy of Sciences and cultured in DMEM/F12 medium supplemented with 10% FBS. The H157 cells were transfected with 100 nM siRNA of RUVBL1 and scramble RNA (siNC) by Lipofectamine 2000. After two independent treatments with siRUVBL1 or siNC, the H157 and Cal-27 cells were incubated and lysed with RIPA buffer. The total protein was isolated, and the concentrations were determined using the bicinchoninic acid (BCA) method (Cat# B0009, Beyo time, China). Standard western blotting was performed, and after sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), the protein was transferred from the gel onto polyvinylidene fluoride (PVDF) membranes. PVDF membranes were blocked using blocking solution (Cat# AR0004, Boster, China) and incubated with anti-β-catenin, anti-RUVBL1, anti-vimentin (Cat# D21H3, Cell Signaling Technology, Shanghai, China), anti-E-cadherin (Cat# 24E10, Cell Signaling Technology), or anti-β-actin antibodies (Cat# A1978, Sigma-Aldrich, Shanghai, China). Immunoreactive proteins were detected by chemiluminescence, and the relative intensity of the gray band was calculated using ImageJ.

2.7. Cell Invasion Assay. A cell invasion assay was used to assess the invasive ability of the H157 and Cal-27 cells in a transwell chamber (8 μm pores, Costar, USA, Cat #. 3422). After transfecting the cells with siRNA, the H157 cells were seeded in the upper chamber with Matrigel matrix (BD Biosciences) and serum-free DMEM/F12 medium. The lower matched 6-well plates contained DMEM/F12 medium supplemented with 10% FBS. After a 48h incubation, the H157 and Cal-27 cells that had invaded the lower membrane surface of the upper chamber were stained with crystal violet (0.05%), scanned, and examined by microscope.

2.8. Western Blotting. After two independent treatments with siRUVBL1 or siNC, the H157 and Cal-27 cells were incubated and lysed with RIPA buffer. The total protein was isolated, and the concentrations were determined using the bicinchoninic acid (BCA) method (Cat# B0009, Beyotime, China). Standard western blotting was performed, and after sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), the protein was transferred from the gel onto polyvinylidene fluoride (PVDF) membranes. PVDF membranes were blocked using blocking solution (Cat# AR0004, Boster, China) and incubated with anti-β-catenin, anti-RUVBL1, anti-vimentin (Cat# D21H3, Cell Signaling Technology, Shanghai, China), anti-E-cadherin (Cat# 24E10, Cell Signaling Technology), or anti-β-actin antibodies (Cat# A1978, Sigma-Aldrich, Shanghai, China). Immunoreactive proteins were detected by chemiluminescence, and the relative intensity of the gray band was calculated using ImageJ.
2.9. Statistical Analysis. RUVBL1 expression in each group of clinical traits was compared by chi-square test using SPSS version 17.0 (SPSS, Inc., USA). \( \chi^2 \) was the chi-square value. *A value of \( p < 0.05 \) was considered significant.

3. Results

3.1. Construction of \( \beta \)-Catenin-Protein Interaction Network and Functional Annotation. Three public OSCC microarray datasets were used to obtain DEGs in OSCC patients. Principal component analysis (PCA) showed that normal and OSCC samples could be clearly separated (Figure 1(a)). Differential expression genes (DEGs) in the three datasets are shown in a volcano plot (Figure 1(b)). Three groups of DEGs from three datasets were combined into one DEG profile. To screen hub genes involved in \( \beta \)-catenin signaling, a BCAP interaction network was constructed, and 170 and 331 genes from STRING and IMEx, respectively, were screened out (Figure 1(c)). Twenty-two genes were selected based on the intersection of DEGs and BCAGs from STRING and IMEx (Figure 1(d)). These genes were used to construct a \( \beta \)-catenin-protein interaction network (Figure 2(a)). Based on the rank of node degree for genes involved in the network, the top fourteen hub genes (node degree > 10) were selected (Figure 2(b)).

To characterize the molecular function of node genes involved in the BCAP network, hub genes were annotated on Metascape (Figure 2(c)). The results of KEGG, Reactome, and GO pathway analyses showed that many hub genes involved in \( \beta \)-catenin signaling were enriched in cancer-related pathways. Some genes were involved in vital signaling pathways, such as cell morphogenesis required for differentiation that occurs via Wnt signaling. Other hub genes are critical for cancer cell survival and growth, playing an important role in epithelial and glial cell development, cell division, and microtubule-based processes.

3.2. Screening of Hub Genes Involved in the \( \beta \)-Catenin-Protein Network. Using GSE37991, six overexpressed and seven downregulated hub genes were found in OSCC versus adjacent nontumor epithelial tissue (Figure 3). Two other microarrays were used to analyze differential hub gene expression (Figures S2 and S3). The Pearson correlation analysis on GEPIA showed that the expression of 12 genes correlated positively with \( \beta \)-catenin expression (\( p < 0.05 \)) (Figure 4). BIRC5 and SLC9A3R1 correlated weakly (\( R < 0.2 \)), AR, CDH2, CDK6, DKK1, MET, PARD3, and
RUVBL1 correlated moderately ($R < 0.3$), GSK3B, MITF, and SMAD7A associated strongly ($p < 0.05$, $R > 0.3$), and ERBB2 and ERBB3 were not associated with β-catenin expression ($p > 0.05$, $R < 0.1$). These findings suggest that aberrant expression of β-catenin correlates with expression of the 12 hub genes. CDH2 expression did not change between the normal and OSCC tissue. Eleven genes were used in the following survival analysis except for ERBB2, ERBB3, and CDH2.

3.3. Association between Overall Survival (OS) and Hub Gene Expression. Eleven hub genes, including SMD7, SLC9A3R1, RUVBL1, PARD3, MITF, MET, GSK3B, DKK1, CDK6, BIRC5, and AR, were used to assess the effect on overall survival using the Mantel-Cox test in GEPIA. An OS heat map showed that log$_{10}$ HR values of DKK1 and RUVBL1 were higher than 0.2 (Figure 5(a)). The Kaplan-Meier curve also showed that high levels of DKK1 and RUVBL1 correlated significantly with poor survival outcomes (log-rank $p < 0.05$) (Figure 5(b)). These results imply that DKK1 and RUVBL1 can predict OS.

3.4. RUVBL1 Is a Hub Gene Involved in β-Catenin Signaling in OSCC. RUVBL1 functions as a component of several chromatin-remodeling complexes and plays an essential role in transcriptional regulation, DNA damage repair, and telomerase activity [14]. In the initial screen of hub genes related to β-catenin, overexpression of RUVBL1 was found in the GSE37991 dataset of OSCC. To further identify the results, a tissue microarray of OSCC samples was used to analyze RUVBL1 expression. Compared to normal oral tissue, RUVBL1 expression was primarily higher in the cytoplasm and nucleus of OSCC (Figure 6). To assess the relationship between RUVBL1 expression and clinical characteristics, RUVBL1 expression was divided into high ($n = 25$) and low ($n = 25$) groups. A relationship analysis was conducted by chi-square, and RUVBL1 expression was correlated with histological grade (Table 1).

Next, the ability of OSCC cell lines to grow and metastasize was measured after the knock-down of RUVBL1 by siRNA transfection. The colony formation assay showed that RUVBL1 siRNA resulted in less H157 cell growth and smaller colony size than the scrambled siRNA (siNC) and vehicle control (Figure 7(a)). The results from the wound healing assay indicated that the gaps of wound healing were getting close after 48 h ($^{\ast}p < 0.05$), but the suppression of RUVBL1 by siRNA delayed the growth and migration of the H157 cells and Cal-27 cells ($^{\ast\ast}p < 0.05$) (Figures 7(b) and 8(a)). In the cell invasion model of transwell, knock-
down of RUVBL1 by siRNA in the H157 and Cal-27 cells significantly prevented cell invasion compared to transfection with siNC and the vehicle control ($p < 0.05$) (Figures 7(c) and 8(b)). Since RUVBL1 was shown to play a role in the $\beta$-catenin pathway, related protein expression was measured after siRNA transfection. RUVBL1, $\beta$-catenin, and vimentin all decreased in both H157 and Cal-27 cells after transfection with siRUVBL1, compared to transfection with siNC and vehicle control (Figures 7(d) and 8(c)). Moreover, E-cadherin expression was elevated in the H157 cells exposed to siRUVBL1. These results imply that knock-down of RUVBL1 by siRNA inhibited OSCC cell growth and metastasis, likely by suppressing $\beta$-catenin signaling.

4. Discussion

While surgical and chemotherapy strategies to treat OSCC have improved significantly, the diagnosis and prognosis of OSCC patients require further investigation. Numerous studies have indicated that cancer cell mutations can promote cell proliferation and metastasis in several cancer types, including OSCC [15, 16]. Wnt/$\beta$-catenin signaling was shown to play a vital role in the tumorigenesis of malignant tumors which promoted an investigation into whether $\beta$-catenin was expressed in the nucleus of OSCC cells [6, 17]. Indeed, beta-catenin expression was found in 87% of well-differentiated OSCC squamous cells and was significantly associated with histological grade ($p < 0.001$) [6]. Other studies showed that nuclear $\beta$-catenin was expressed in 35.9% of adjacent and 44.4% of "distant" OSCC samples [12]. Dysregulation of miRNA 34a-5p [18] and miR-106a [19], IncRNA MINCR [20], FTH1P3 [21], CCAT1 [22], and MEG3 [23] activated Wnt/$\beta$-catenin signaling to promote cell proliferation and migration in OSCC. Evidence indicates that targeting $\beta$-catenin using specific inhibitors and siRNA abrogated $\beta$-catenin-induced malignant growth of OSCC and enhanced sensitivity to chemotherapeutics [24–28].

Given the aberrant activation of $\beta$-catenin signaling in OSCC, screening for $\beta$-catenin-related proteins that can serve as novel biomarkers is essential to better understand this disease. Based on the differential expression of genes in OSCC and $\beta$-catenin-associated genes in the $\beta$-catenin protein network, 22 genes were selected from the intersection of DEGs and $\beta$-catenin-associated genes in the STRING and IMEx databases. These 22 potential $\beta$-catenin-associated genes were used to construct a $\beta$-catenin-protein network, and the top 14 genes (node degree $> 10$) were chosen. Signaling pathway enrichment analysis indicated that many hub genes were enriched in cancer-related pathways and essential signaling pathways related to cell growth, survival, and differentiation. Pearson’s correlation analysis was performed, and the results showed that 12 hub genes containing AR, BIRC5, CDH2, CDK6, DKK1, GSK3B, MET, MITF, PARD3, RUVBL1, SLCA9A3R1, and SMAD7 were significantly related to $\beta$-catenin expression, except ERBB2 and ERBB3. Eleven genes were used to analyze overall survival except for ERBB2, ERBB3, and CDH2.

To determine whether hub BCAG expression was a prognostic indicator for OSCC, an overall survival heat map of 11 hub genes analyzed using the Mantel-Cox test showed that only two genes influenced overall survival (log-rank $p < 0.05$). The Kaplan-Meier curve also showed that high expression of DKK1 and RUVBL1 was associated with poor survival outcomes. Many studies have shown that DKK1 plays various roles in Wnt signaling during several cancers [29–32], which correlates with the overall survival of OSCC patients [33]. While DKK1 is frequently upregulated in OSCC-derived cell lines and primary OSCCs compared with normal cells, DKK1-positive patients have a low risk of regional lymph node metastasis [29]. Further study is necessary to interpret these conflicting findings and better understand the relationship between DKK1 and the clinical traits of OSCC.

The present study focused on RUVBL1, another $\beta$-catenin-associated protein. RUVBL1, known as TIP49 or Pontin, exhibits weak ATPase activity. This gene is an essential component of the TIP60 complex [34], which accompanies and modulates transcription factors, including MYC, E2F1, and $\beta$-catenin, and is involved in chromatin remodeling that contributes to carcinogenesis [35]. The upregulation and nuclear localization of RUVBL1 along with $\beta$-catenin are highly correlated with colorectal carcinoma progression, which enhances TCF/$\beta$-catenin-mediated transcription of Wnt target genes and may thus promote carcinogenesis [36, 37]. Non-small-cell lung cancer (NSCLC) patients with poor survival outcomes also had higher RUVBL1 and RUVBL2 expression in NSCLC [38]. Notably, a RUVBL1 mutant protein, TIP49-D302N, interacted with $\beta$-catenin and occupied the position of RUVBL1, thus inhibiting $\beta$-catenin-mediated activation of TCF-dependent neoplastic cellular genes [39]. Inhibition of the $\beta$-catenin/TCF-dependent genes, ITF2 and Axil, was seen using small interfering RNA against endogenous RUVBL1 [39].

| Variable          | Total | Low | High | $p$ value | $X^2$ |
|-------------------|-------|-----|------|-----------|-------|
| Age               |       |     |      |           |       |
| $\leq 50$         | 18    | 11  | 7    | 0.189     | 1.389 |
| $>50$             | 32    | 14  | 18   |           |       |
| Gender            |       |     |      |           |       |
| Male              | 28    | 13  | 15   | 0.325     | 0.388 |
| Female            | 22    | 12  | 10   |           |       |
| Histological grade|       |     |      |           |       |
| G1                | 38    | 23  | 15   | 0.005*    | 8.084 |
| G2+G3             | 10    | 1   | 9    |           |       |
| Stage             |       |     |      |           |       |
| I+II              | 44    | 24  | 20   | 0.095     | 3.030 |
| III+IV            | 6     | 1   | 5    |           |       |
| TNM stage         |       |     |      |           |       |
| T1                | 20    | 11  | 9    | 0.387     | 0.333 |
| T2+T3             | 30    | 14  | 16   |           |       |

$X^2$ was chi-square value. *A value of $p < 0.05$ was considered as significant difference.
Figure 7: Knock-down of RUVBL1 by siRNA attenuated growth and metastasis of the OSCC cell line, H157, by inhibiting β-catenin signaling. (a) Knock-down of RUVBL1 by siRNA suppressed H157 cell proliferation as indicated using the colony formation assay. The box plot showed the number of cells. (b) Knock-down of RUVBL1 by siRNA inhibited migration of the H157 cells in the wound healing assay. Significant differences between groups were assessed using a Student’s T test and shown by * and #, p < 0.05. (c). After transfection of the H157 cells with RUVBL1 siRNA or scramble siRNA (siNC), cell invasive ability was determined by cell invasion assay. All experiments were performed in triplicate. Significant differences between groups were assessed using a Student’s T test and shown by * and #, p < 0.05. (d) Expression of β-catenin pathway proteins was detected by western blot analysis. Intensity of the gray band was calculated by ImageJ and shown in the figure.
The findings indicated that RUVBL1 was overexpressed in the cytoplasm and nucleus of OSCC cells by IHC. In addition, RUVBL1 expression was significantly related to the histological grade of OSCC (p = 0.005). Pearson’s relation analysis showed that RUVBL1 was positively related to β-catenin (p = 0.003) in HNSC data of TCGA using GEPIA (Figure 4). Thus, RUVBL1 is likely to be a positive modulator of β-catenin signaling. Knock-down of RUVBL1 by siRNA was shown to contribute to the lower cell number and small size of the H157 cell colony compared to cells transfected with scrambled siRNA (siNC) and vehicle control. Fewer cells were transfected with siRUVBL1 on the membrane of the upper chamber than were transfected with siNC and vehicle control, indicating that knock-down of RUVBL1 significantly decreased the invasive ability of the H157 cells. Involvement of RUVBL1 in the β-catenin signaling pathway showed that RUVBL1, β-catenin, and vimentin expression were reduced in the H157 cells. It was also found that RUVBL1 suppression by siRNA could decrease the migration and growth of the Cal-27 cells. Interestingly, E-cadherin expression was elevated in the H157 cells exposed to siRUVBL1. These results suggest that RUVBL1 knockdown inhibited the growth and metastasis of an OSCC cell line by inactivating β-catenin signaling. Recently, RUVBL1,

![Figure 8](image.png)
a component of R2TP, a well-conserved molecular chaperone complex, was shown to be required for HSC-4 cell proliferation and migration [40]. The present study provides additional evidence that RUVBL1 enhances the invasive and migration ability of OSCC cell lines, likely by interacting and activating β-catenin-driven transcription. More in-depth experiments of the molecular mechanisms of RUVBL1 in OSCC require future investigation.

5. Conclusions
RUVBL1 expression is a favorable biomarker for predicting the overall survival of OSCC patients. In addition, knockdown of RUVBL1 in the H157 cells showed that this gene is a potential diagnostic and prognostic biomarker, as well as a target for OSCC treatment. Further investigation of RUVBL1 may reveal additional molecular mechanisms of β-catenin-driven OSCC tumorigenesis.

Data Availability
The data used to support the findings of this study are available from the NCBI Gene Expression Omnibus (GEO) (https://www.ncbi.nlm.nih.gov/geo/), and the code would be supplied from the corresponding author upon request.

Conflicts of Interest
The authors declared no potential conflicts of interest regarding research, authorship, and/or publication of this article.

Acknowledgments
We are grateful to Miss Haiwen Zhang and Zhaohui Jiang from the Central South University in China for the bioinformatics analysis. We are also grateful to The Cancer Genome Atlas (TCGA) project and NCBI GEO database and their contributors for this valuable public data set. This research was funded by the Key Research and Development Program of Jiangxi Province (20192BBGL70017).

Supplementary Materials
Figure S1: an overall flowchart about the analysis pipeline. Figure S2: expression of genes in GSE30784. Box plot of β-catenin-associated hub gene expression in GSE30784. *p value < 0.05 indicates a significant difference between the OSCC and normal tissue groups. Figure S3: expression of genes in GSE31056. Box plot of β-catenin-associated hub gene expression in GSE31056. *p value < 0.05 indicates a significant difference between the OSCC and normal tissue groups. Table S1: the sequences of siRNA of RUVBL1 and scramble control. (Supplementary Materials)

References
[1] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: a Cancer Journal for Clinicians, vol. 68, no. 6, pp. 394–424, 2018.
[2] R. M. Feng, Y. N. Zong, S. M. Cao, and R. H. Xu, “Current cancer situation in China: good or bad news from the 2018 global cancer statistics?,” Cancer Communications, vol. 39, no. 1, p. 22, 2019.
[3] J. Noguti, C. F. de Moura, T. A. Hossaka et al., “The role of canonical WNT signaling pathway in oral carcinogenesis: a comprehensive review,” Anticancer Research, vol. 32, no. 3, pp. 873–878, 2012.
[4] J. Palusczak, K. Kiwerska, and D. Mielcarek-Kuchta, “Frequent methylation of DAB2, a Wnt pathway antagonist, in oral and oropharyngeal squamous cell carcinomas,” Pathology, Research and Practice, vol. 214, no. 2, pp. 314–317, 2018.
[5] Z. Li, H. Jin, G. Mao, L. Wu, and Q. Guo, “Msi2 plays a carcinogenic role in esophageal squamous cell carcinoma via regulation of the Wnt/beta-catenin and Hedgehog signaling pathways,” Experimental Cell Research, vol. 361, no. 1, pp. 170–177, 2017.
[6] K. W. Zaid, “Immunohistochemical assessment of E-cadherin and β-catenin in the histological differentiations of oral squamous cell carcinoma,” Asian Pacific Journal of Cancer Prevention, vol. 15, no. 20, pp. 8847–8853, 2014.
[7] F. Mahomed, M. Altini, and S. Meer, “Altered E-cadherin/β-catenin expression in oral squamous carcinoma with and without nodal metastasis,” Oral Diseases, vol. 13, no. 4, pp. 386–392, 2007.
[8] Z. G. Cai, X. J. Shi, Y. Gao, M. J. Wei, C. Y. Wang, and G. Y. Yu, “Beta-catenin expression pattern in primary oral squamous cell carcinoma,” Chinese Medical Journal, vol. 121, no. 19, pp. 1866–1870, 2008.
[9] P. V. Angadi, P. V. Patil, V. Angadi et al., “Immunoeexpression of epithelial mesenchymal transition proteins E-cadherin, β-catenin, and N-cadherin in oral squamous cell carcinoma,” International Journal of Surgical Pathology, vol. 24, no. 8, pp. 696–703, 2016.
[10] W. Kildal, B. Risberg, V. M. Abeler et al., “β-Catenin expression, DNA ploidy and clinicopathological features in ovarian cancer: a study in 253 patients,” European Journal of Cancer, vol. 41, no. 8, pp. 1127–1134, 2005.
[11] S. Siriwardena, T. Tsunematsu, G. Qi, N. Ishimaru, and Y. Kudo, “Invasion-related factors as potential diagnostic and therapeutic targets in oral squamous cell carcinoma—a review,” International Journal of Molecular Sciences, vol. 19, no. 5, p. 1462, 2018.
[12] M. A. Moles, J. A. Montoya, M. D. Salvago, I. R. Avila, J. J. Campillo, and M. Bravo, “Implications of differential expression of β-catenin in oral carcinoma,” Anticancer Research, vol. 36, no. 4, pp. 1599–1604, 2016.
[13] N. T. Doncheva, J. H. Morris, J. Gorodkin, and L. J. Jensen, “Cytoscape StringApp: network analysis and visualization of proteomics data,” Journal of Proteome Research, vol. 18, no. 2, pp. 623–632, 2019.
[14] Y. Q. Mao and W. A. Houry, “The role of Pontin and Reptin in cellular physiology and cancer etiology,” Frontiers in Molecular Biosciences, vol. 4, p. 58, 2017.
[15] T. R. Shao, Z. N. Zheng, Y. C. Chen et al., “LncRNA AC007271.3 promotes cell proliferation, invasion, migration and inhibits cell apoptosis of OSCC via the Wnt/β-catenin signaling pathway,” Life Sciences, vol. 239, 2019.
B. Ahmad, M. Asif, A. Ali, S. Jamal, M. Z. Khan, and M. T. Khadem, “Expression of K1-67 and beta-catenin in Pseudopapillomatous hyperplasia and squamous cell carcinoma in oral mucosal biopsies: an immunohistochemical study,” *Asian Pacific Journal of Cancer Prevention*, vol. 21, no. 1, pp. 157–161, 2020.

P. Balasundaram, M. K. Singh, A. K. Dinda, A. Thakar, and R. Yadav, “Study of beta-catenin, E-cadherin and vimentin in oral squamous cell carcinoma with and without lymph node metastases,” *Diagnostic Pathology*, vol. 9, no. 1, p. 145, 2014.

Y. Y. Li, Y. W. Tao, S. Gao et al., “Cancer-associated fibroblasts contribute to oral cancer cells proliferation and metastasis via exosome-mediated paracrine miR-34a-5p,” *eBioMedicine*, vol. 36, pp. 209–220, 2018.

N. Zhang, Z. L. Wei, J. Yin, L. Zhang, J. Wang, and Z. L. Jin, “MiR-106a-3p inhibits oral squamous cell carcinoma progression by directly targeting MeCP2 and suppressing the Wnt/ beta-catenin signaling pathway,” *American Journal of Translational Research*, vol. 10, no. 11, pp. 3542–3554, 2018.

Q. Lyu, L. Jin, X. Yang, and F. Zhang, “LncRNA MINCR activates Wnt/beta-catenin signals to promote cell proliferation and migration in oral squamous cell carcinoma,” *Pathology, Research and Practice*, vol. 215, no. 5, pp. 924–930, 2019.

M. Liu, X. Gao, and C. L. Liu, “Increased expression of IncRNA FTH1P3 promotes oral squamous cell carcinoma cells migration and invasion by enhancing PI3K/Akt/GSK3b/ Wnt/beta-catenin signaling,” *European Review for Medical and Pharmacological Sciences*, vol. 22, no. 23, pp. 8306–8314, 2018.

G. H. Li, Z. H. Ma, and X. Wang, “Long non-coding RNA CCAAT1 is a prognostic biomarker for the progression of oral squamous cell carcinoma via miR-181a-mediated Wnt/beta-catenin signaling pathway,” *Cell Cycle*, vol. 18, no. 21, pp. 2902–2913, 2019.

Z. Liu, C. Wu, N. Xie, and P. Wang, “Long non-coding RNA MEG3 inhibits the proliferation and metastasis of oral squamous cell carcinoma by regulating the WNT/beta-catenin signaling pathway,” *Oncology Letters*, vol. 14, no. 4, pp. 4053–4058, 2017.

C. H. Hsieh, H. H. Hsu, M. A. Shibu et al., “Down-regulation of beta-catenin and the associated migration ability by Taiwanin C in arecoline and 4-NQO-induced oral cancer cells via GSK-3beta activation,” *Molecular Carcinogenesis*, vol. 56, no. 3, pp. 1055–1067, 2017.

J. Tian, X. Cui, Y. Feng, and L. Gu, “Inhibition of WNT7A-beta-catenin signaling pathway sensitizes oral squamous cell carcinoma to cisplatin,” *International Journal of Clinical and Experimental Pathology*, vol. 11, no. 10, pp. 4926–4933, 2018.

L. H. Wang, M. Xu, L. Q. Fu, X. Y. Chen, and F. Yang, “The antihelminthic niclosamide inhibits cancer stemness, extracellular matrix remodeling, and metastasis through dysregulation of the nuclear beta-catenin/c-Myc axis in OSCC,” *Scientific Reports*, vol. 8, no. 1, p. 12776, 2018.

Y. Xie, L. Zhong, D. Duan, and T. Li, “Castolin inhibits invasion and proliferation via downregulation of beta-catenin and reversion of EMT in oral squamous cell carcinoma,” *Journal of Oral Pathology & Medicine*, vol. 48, no. 10, pp. 897–905, 2019.

C. Zhang, Y. Hao, Y. Sun, and P. Liu, “Quercetin suppresses the tumorigenesis of oral squamous cell carcinoma by regulating microRNA-22/WNT1/beta-catenin axis,” *Journal of Pharmacological Sciences*, vol. 140, no. 2, pp. 128–136, 2019.

K. Ogoshi, A. Kasamatsu, M. Iyoda et al., “Dickkopf-1 in human oral cancer,” *International Journal of Oncology*, vol. 39, no. 2, pp. 329–336, 2011.

O. V. Grinchuk, S. P. Yenamandra, R. Iyer et al., “Tumor-adjacent tissue co-expression profile analysis reveals oncogenic ribosomal gene signature for prognosis of resectable hepatocellular carcinoma,” *Molecular Oncology*, vol. 12, no. 1, pp. 89–113, 2018.

Z. Wang, J. Wang, Z. Chen, K. Wang, and L. Shi, “MicroRNA-1-3p inhibits the proliferation and migration of oral squamous cell carcinoma cells by targeting DKK1,” *Biochemistry and Cell Biology*, vol. 96, no. 3, pp. 355–364, 2018.

R. Zhang, H. M. Lin, R. Broering et al., “Dickkopf-1 contributes to hepatocellular carcinoma tumorigenesis by activating the Wnt/beta-catenin signaling pathway,” *Signal Transduction and Targeted Therapy*, vol. 4, no. 1, p. 54, 2019.

B. Yu, X. Yang, Y. Xu et al., “Elevated expression of DKK1 is associated with cytoplasmic/nuclear beta-catenin accumulation and poor prognosis in hepatocellular carcinomas,” *Journal of Hepatology*, vol. 50, no. 5, pp. 948–957, 2009.

S. Jha, A. Gupta, A. Dar, and A. Dutta, “RVBs are required for assembling a functional TIP60 complex,” *Molecular and Cellular Biology*, vol. 33, no. 6, pp. 1164–1174, 2013.

K. A. Dugan, M. A. Wood, and M. D. Cole, “TIP49, but not TIP49A, modulates c-Myc and E2F1 dependent apoptosis,” *Oncogene*, vol. 21, no. 38, pp. 5835–5843, 2002.

J. C. Lauscher, C. Loddenkemper, L. Kosel, J. Grone, H. J. Buhr, and O. Huber, “Increased pontin expression in human colo-rectal cancer tissue,” *Human Pathology*, vol. 38, no. 7, pp. 978–985, 2007.

J. C. Lauscher, S. Elezkurtaj, S. Dullat et al., “Increased Pontin expression is a potential predictor for outcome in sporadic colo-rectal carcinoma,” *Oncology Reports*, vol. 28, no. 5, pp. 1619–1624, 2012.

P. Yenerall, A. K. Das, S. Wang et al., “RUVBL1/RUVBL2 ATPase activity drives PAQosome maturation, DNA replication and radioresistance in lung cancer,” *Cell Chemical Biology*, vol. 27, no. 1, 2020.

Y. Feng, N. Lee, and E. R. Fearon, “TIP49 regulates beta-catenin-mediated neoplastic transformation and T-cell factor target gene induction via effects on chromatin remodeling,” *Cancer Research*, vol. 63, no. 24, pp. 8726–8734, 2003.

T. Kiguchi, Y. Kakihara, M. Yamazaki et al., “Identification and characterization of R2TP in the development of oral squamous cell carcinoma,” *Biochemical and Biophysical Research Communications*, vol. 548, pp. 161–166, 2021.